Format

Send to

Choose Destination
Drugs Today (Barc). 2012 Apr;48 Suppl A:63-9. doi: 10.1358/dot.2012.48(Suppl.A).1739724.

Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.

Author information

1
Department of Psychiatry, University of Rostock, Rostock, Germany. johannes.thome@med.uni-rostock.de

Abstract

The safety of Cerebrolysin has been shown through many years of clinical use, observations from postmarketing surveillance studies, and safety data from randomized, controlled clinical trials. The reported events showed that adverse reactions to Cerebrolysin were generally mild and transient. Most common adverse events included vertigo, agitation and feeling hot. In the controlled clinical trials analyzed for this report, the incidence of adverse events was similar in Cerebrolysin- and placebo-treated groups. Cerebrolysin seems to be safe when used in combination with recombinant tissue-type plasminogen activator or cholinesterase inhibitors such as donepezil or rivastigmine. To our knowledge, Cerebrolysin was not associated with major changes in vital signs or laboratory parameters.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clarivate Analytics
Loading ...
Support Center